Roche is looking at multiple new biomarkers and targets for immunotherapy while it aggressively pursues a leadership spot in the PD-1/L1 space with its expansive atezolizumab program.
The emerging immunotherapy portfolio was presented by execs from the research and early development arms of both Genentech Inc. (gRED) and Roche (pRED) during Roche's May 31 analyst briefing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?